PBLS Parabilis Medicines, Inc.
Price Chart
Executive Summary
Mathai Mammen, President & CEO of Parabilis Medicines, filed a Form 3 initial statement of beneficial ownership, disclosing stock options for approximately 5.24 million shares at exercise prices ranging from $1.48 to $3.43. This is a routine filing required upon becoming an insider and provides no new information about the company's operations or financial performance.
Actionable Insight
This Form 3 is a standard initial beneficial ownership filing with no trading activity or material news. Monitor future Form 4 filings for any open-market purchases or sales by the CEO, which could provide signals about insider conviction.
Key Facts
- Mathai Mammen filed Form 3 as President & CEO of Parabilis Medicines, Inc.
- Disclosed stock options to purchase approximately 5,237,155 shares of common stock.
- Options have exercise prices of $1.48, $3.14, and $3.43 per share.
- Options vest over time subject to continued service, with some performance-based vesting conditions.
- Filing includes a Limited Power of Attorney authorizing Teresa Jurgensen and Thomas Kotarakos to file future Section 16 and Schedule 13D/G forms.
Financial Impact
No financial impact; Form 3 is a routine insider ownership disclosure with no transaction or change in company fundamentals.
Risk Factors
- No material risks identified from this filing.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-264599 |
| Document: 0001193125-26-264599-index-headers.html | 0001193125-26-264599 |
| Document: 0001193125-26-264599-index.html | 0001193125-26-264599 |
| Document: 0001193125-26-264599.txt | 0001193125-26-264599 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $30.30 awaiting T+20 | awaiting T+20 | — | $27.26 (−10.03%) |
|
Jun 10, 2026
4d ago
|
424B4
| $32.16 awaiting T+20 | awaiting T+20 | — | $27.26 (−15.24%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access